VADERIS THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $152 MILLION SERIES B FINANCING AND INITIATION OF THE GLOBAL PHASE 3 HEROIC STUDY OF ENGASERTIB FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA

Reuters · 2d ago

Please log in to view news